Persistent mood [affective] disorder
Methodology & AI Transparency ⓘ
Persistent mood [affective] disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Persistent mood [affective] disorder is an ICD-10-CM indexed diagnosis (F34.9) within Depression, Bipolar & Mood Disorders.
- 2 Real-world patient consensus: Mapped to Depression, Bipolar & Mood Disorders under ICD-10-CM F34.9 for Persistent mood [affective] disorder clinical workups.
- 3 Typical cash cost range: Workup highlights for Persistent mood [affective] disorder (F34.9): sleep-wake rhythm assessment [Persistent mood [affective] disorder F34.9].
- 4 Top reported side effects / signs: Objective lab/clinical target for Persistent mood [affective] disorder: Serum Vitamin D in Persistent mood [affective] disorder (F34.9: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F34.9)) and PHQ-9 Symptom Severity in Persistent mood [affective] disorder (F34.9: Score).
Ask our AI Specialists anything about Persistent mood [affective] disorder
What Is Persistent mood [affective] disorder?
Persistent mood [affective] disorder is an ICD-10-CM indexed diagnosis (F34.9) within Depression, Bipolar & Mood Disorders. Clinical evaluation centers on sleep-wake rhythm assessment [Persistent mood [affective] disorder F34.9] alongside serial Serum Vitamin D in Persistent mood [affective] disorder (F34.9: & RBC Folate) tracking (25(OH)D 40 – 65 ng/mL (F34.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in depression & mood, Persistent mood [affective] disorder (F34.9) involves prefrontal-limbic circuit dysregulation [Persistent mood [affective] disorder F34.9]. progression correlates with shifts in Serum Vitamin D in Persistent mood [affective] disorder (F34.9: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F34.9)).
Common Symptoms & Clinical Signs
- • Presentation of Persistent mood [affective] disorder (F34.9): disrupted sleep architecture [Persistent mood [affective] disorder F34.9]
- • Secondary Persistent mood [affective] disorder clinical sign: slowed concentration, indecisiveness, in Persistent mood [affective] disorder (F34.9: and physical heaviness)
- • Symptom flares in Persistent mood [affective] disorder correlating with Serum Vitamin D in Persistent mood [affective] disorder (F34.9: & RBC Folate) deviation outside 25(OH)D 40 – 65 ng/mL (F34.9)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Persistent mood [affective] disorder F34.9] evaluation (F34.9)
Persistent mood [affective] disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F34.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin D in Persistent mood [affective] disorder (F34.9: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F34.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Persistent mood [affective] disorder (F34.9: Score) | < 4 (clinical remission) (F34.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Persistent mood [affective] disorder (F34.9: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F34.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Persistent mood [affective] disorder
Treatment selection for Persistent mood [affective] disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Persistent mood [affective] disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on A Decision-Support System to Personalize Antidepressant Treatment in depression:: What a 540-Participant Study Found Of the 520 eligible participants, 493 were included in the primary analysis (median age, 35 [IQR, 25 to 48] years; 58% female; PHQ-9 mean score, 16.6 [SD, 5.1]; GAD-7 mean score, 11.5 [SD, 4.1]). JAMA • 2026-04-14 • Randomized Controlled Trial | N = 540 | 93/100 | PMID 41779422 ↗ |
| New Insights on Benefits and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in: What a 330-Participant Study Found Once daily VI/FF pMDI was non-inferior to twice daily FOR/FP pMDI in patients with persistent asthma. The Journal of asthma : official journal of the Association for the Care of Asthma • 2024-10-15 • Phase III Randomized Trial | N = 330 | 93/100 | PMID 38488853 ↗ |
| What the Latest Evidence Really Says About Vasodilators for persistent lung high blood pressure of the newborn: A network Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN. Pediatric pulmonology • 2024-12-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39193897 ↗ |
| New Insights on Effect-size seed-based d mapping of resting-state fMRI for persistent trouble: What a 951-Participant Study Found The altered functional networks in patients with persistent trouble sleeping disorder converge in median cingulate/paracingulate gyri and right parahippocampal gyrus with increased activity, and cerebellum and superior frontal... Sleep & breathing = Schlaf & Atmung • 2020-06-15 • Meta-Analysis | N = 951 | 91/100 | PMID 31865507 ↗ |
Persistent mood [affective] disorder Patient Community & “People Like Me” Threads
Filter Persistent mood [affective] disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.